What it is
Foundayo is orforglipron, approved 1 April 2026. It is taken by mouth. The label does not impose food or water timing restrictions. That is the fact that separates it from the Wegovy pill in a household schedule.
This page is a coverage-and-routine file, not prescribing information. Read the current insert. VitalHound does not diagnose or treat.
Legal price options
Medicare GLP-1 Bridge: $50 per month if eligible and the PA is approved, 1 July 2026–31 December 2027. The $50 does not count toward TrOOP. Extra Help does not apply.
Commercial plus manufacturer card: often about $25 when the plan covers the drug and the member is not on government coverage. Cash via LillyDirect: often about $149 at the lowest dose. Telehealth bundles near $449 are usually worse than cash plus a local visit.
When it is the wrong Medicare path
If the prescription is for type 2 diabetes, moderate-to-severe OSA, or MASH, use Part D rules, not Bridge. If a 2026 Part D GLP-1 already filled, Bridge is generally closed.
Sister products people conflate
Zepbound is also Lilly and is injectable; Bridge allows KwikPen only. Wegovy pill is oral but has an empty-stomach window and a different cash calendar (4 mg $149 until 31 August 2026, then $199).
What the checklist should name
Foundayo, not 'the oral GLP-1.' Indication. Dated BMI. Morning meds only as context — they do not collide with a food window here, but they still belong in the chart.
Questions
Is Foundayo on Bridge?
Does it need an empty stomach?
Is orforglipron the same as semaglutide?
Can Medicare use the ~$25 card?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options